<DOC>
	<DOC>NCT00545025</DOC>
	<brief_summary>The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.</brief_summary>
	<brief_title>Revaccination With Influenza Vaccine GSK1247446A</brief_title>
	<detailed_description>The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female aged 1860 years old at the time of vaccination, who previously participated in 108656 clinical trial. Subjects who the investigator believes that they can and will comply with the requirements of the protocol. Written informed consent obtained from the subject. Free of obvious health problems as established by medical history and clinical examination before entering into the study. If the subject is female, she must be of nonchildbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine within 30 days preceding the administration of the study vaccine, or planned use during the study period. Planned administration of an influenza vaccine other than the study vaccines during the entire study period Previous vaccination against influenza since January 2007. Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. Chronic administration of immunosuppressants or other immunemodifying drugs within three months prior to the first vaccine dose. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination Administration of immunoglobulins and/or any blood products within three months preceding the dose of study vaccine or planned administration during the study period. History of hypersensitivity to a previous dose of influenza vaccine. History of confirmed influenza infection within the last 12 months. Pregnancy. History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) Acute disease at the time of enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>